UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of 

the Securities Exchange Act of 1934

 

Filed by the Registrant x

 

Filed by a Party other than the Registrant ¨

 

Check the appropriate box:

 

¨Preliminary Proxy Statement

 

¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

¨Definitive Proxy Statement

 

xDefinitive Additional Materials

 

¨Soliciting Material under §240.14a-12

 

ONCONOVA THERAPEUTICS, INC. 

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

xNo fee required.

 

¨Fee paid previously with preliminary materials.

 

¨Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

 

  

Onconova Therapeutics, Inc., a Delaware corporation (the “Company”), is filing materials contained in this Schedule 14A with the U.S. Securities and Exchange Commission (the “SEC”) as definitive additional materials pursuant to Rule 14a-6(b) under the Securities Exchange Act of 1934, as amended, in connection with the solicitation of proxies by the Board of Directors for the Company’s 2023 Annual Meeting of Stockholders held on July 21, 2023 (the “Annual Meeting”). On June 7, 2023, the Company filed a definitive proxy statement (the “Annual Meeting Proxy Statement”) and a definitive form of proxy card with the SEC in connection with the Annual Meeting.

 

These definitive additional materials were first sent or made available to stockholders on or about June 8, 2023.

 

Certain Information Disclosed in the Current Report on Form 8-K the Company Filed with the SEC on July 21, 2023

 

As disclosed in the Form 8-K, on July 21, 2023, the Company called to order the Annual Meeting. At the Annual Meeting, there were not present or represented by proxy a sufficient number of shares of the Company’s common stock in order to constitute quorum. The Company adjourned the Annual Meeting until August 10, 2023 at 9:00 a.m. Eastern Daylight Time (the “Reconvened Annual Meeting”).

 

The Reconvened Annual Meeting will be held at the same virtual meeting location, www.virtualshareholdermeeting.com/ONTX2023. This will enable the Company’s stockholders of record as of the record date, which was May 23, 2023, additional time to consider and vote on the proposals, and enable the Company’s proxy solicitor, Alliance Advisors, LLC, more time to assist the Company with the solicitation of stockholder votes on the proposals.

 

At the Reconvened Annual Meeting, stockholders will be deemed to be present in person and vote at such adjourned meeting in the same manner as disclosed in the Annual Meeting Proxy Statement. Valid proxies submitted prior to the Annual Meeting will continue to be valid for the Reconvened Annual Meeting, unless properly changed or revoked prior to votes being taken at the Reconvened Annual Meeting.

 

 

 

 

Onconova Therapeutics (NASDAQ:ONTX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Onconova Therapeutics.
Onconova Therapeutics (NASDAQ:ONTX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Onconova Therapeutics.